The Oncoprotein Set/TAF-Iβ, an Inhibitor of Histone Acetyltransferase, Inhibits Active Demethylation of DNA, Integrating DNA Methylation and Transcriptional Silencing*

Received for publication, March 7, 2002, and in revised form, April 25, 2002
Published, JBC Papers in Press, April 26, 2002, DOI 10.1074/jbc.M202256200

Nadia Cervoni‡, Nancy Detich‡, Sang-beom Seo§, Debabrata Chakravarti§, and Moshe Szyf‡†

From the ‡Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec H3G 1Y6, Canada and the §Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104

Histone hypoacetylation and DNA hypermethylation are hallmarks of gene silencing. Although a role for DNA methylation in regulating histone acetylation has been established, it is not clear how and whether epigenetic histone markings influence DNA modifications in transcriptional silencing. We have previously shown that induction of histone acetylation by trichostatin A promotes demethylation of ectopically methylated DNA (Cervoni, N., and Szyf, M. (2001) J. Biol. Chem. 276, 40778–40787). The oncoprotein Set/TAF-Iβ is a subunit of the recently identified inhibitor of acetyltransferases complex that inhibits histone acetylation by binding to and masking histone acetyltransferase targets (Seo, S. B., McNamara, P., Heo, S., Turner, A., Lane, W. S., and Chakravarti, D. (2001) Cell 104, 119–130). We show here that the overexpression of Set/TAF-Iβ, whose expression is up-regulated in multiple tumor tissues, inhibits demethylation of ectopically methylated DNA resulting in gene silencing. Overexpression of a mutant Set/TAF-Iβ that does not inhibit histone acetylation is defective in inhibiting DNA demethylation. Taken together, these results are consistent with a novel regulatory role for Set/TAF-Iβ, integrating epigenetic states of histones and DNA in gene regulation and provide a new mechanism that can explain how hypermethylation of specific regions might come about by inhibition of demethylation in cancer cells.

The DNA methylation pattern is tightly correlated with chromatin structure in that transcriptionally active chromatin domains are hypomethylated, whereas inactive regions are hypermethylated (3). However, the mechanisms defining the relationship between histone hypoacetylation and DNA hypermethylation are not clear. While it is well accepted that DNA methylation can promote chromatin deacetylation and inactivation (4), a number of studies suggest that chromatin status can also alter the pattern of DNA methylation. Genome wide demethylation can promote chromatin deacetylation and inactivation (4), a number of studies suggest that chromatin status can also alter the pattern of DNA methylation. Genome wide demethylation is a consequence of increased DNA methylation or reduced demethylation of a gene in a proliferating cell is passive, resulting from inhibition of DNA methylation during DNA synthesis or an active true removal of a methyl group. We have therefore recently developed a transient transfection system that enables studying demethylase activity in cancer cells. A reporter CMV-GFP construct is methylated in vitro by a CpG methyltransferase mSss1 and introduced into human transformed HEK293 cells. The plasmid is extracted 96 h after transfection, and its state of methylation is determined by either methylation sensitive restriction enzyme analysis or bisulfite mapping. Since we have demonstrated that this plasmid does not replicate in HEK cells (1), any change in DNA methylation must result from active demethylation. We have also shown that these constructs are not de novo methylated during the transient transfection period, and therefore the transient transfection assay measures exclusively active demethylation in the cell. This system could be utilized to measure the effects of specific histone deacetylase, was shown to induce selective loss of DNA methylation in Neurospora (6), and very recently disruption of histone methylation was shown to eliminate DNA methylation in Neurospora (7). We have recently shown that TSA can induce demethylation of ectopically methylated genes (1).

Hypermethylation of CpG islands has attracted considerable attention as a mechanism responsible for gene silencing during tumor suppression. It is clear that methylation of tumor suppressor genes cannot be explained by the increase in the general level of DNA methyltransferase activity observed in cancer cells. Significant effort has been therefore directed toward identification of factors that recruit DNA methyltransferases to specific promoters. In accordance with this hypothesis, a recent publication demonstrated that the oncogenic transcription factor PML-RAR fusion protein recruits DNMT1 to the retinoic acid βII promoter, resulting in methylation and silencing of this promoter (8).

An alternative potential mechanism of bringing about DNA hypermethylation is inhibition of demethylase activity. This possibility was not previously explored, since it has long been believed that the DNA methylation pattern is controlled exclusively by DNA methyltransferases and that the DNA methylation reaction is irreversible. Nevertheless, we have recently extracted DNA demethylase activity from human lung cancer cell line A549 (9) and have shown that a human embryonal kidney cell line HEK293 possesses active demethylase activity (1).

The DNA methylation state of a gene in a living cell represents a steady state, and it is hard to determine whether it is a consequence of increased DNA methylation or reduced demethylation. Moreover, it is hard to determine whether demethylation of a gene in a proliferating cell is passive, resulting from inhibition of DNA methylation during DNA synthesis or an active true removal of a methyl group. We have therefore recently developed a transient transfection system that enables studying demethylase activity in cancer cells. A reporter CMV-GFP construct is methylated in vitro by a CpG methyltransferase mSss1 and introduced into human transformed HEK293 cells. The plasmid is extracted 96 h after transfection, and its state of methylation is determined by either methylation sensitive restriction enzyme analysis or bisulfite mapping. Since we have demonstrated that this plasmid does not replicate in HEK cells (1), any change in DNA methylation must result from active demethylation. We have also shown that these constructs are not de novo methylated during the transient transfection period, and therefore the transient transfection assay measures exclusively active demethylation in the cell. This system could be utilized to measure the effects of specific histone deacetylase.
proteins on active demethylation of specific sequences in living cells. Using this system we have recently shown that histone acetylation stimulates active demethylation of ectopically methylated reporter constructs.

Although we have shown that TSA treatment could potentially stimulate demethylation, this effect is not universal, and it is clear that many methylated genes are neither demethylated nor activated following TSA treatment (10). We therefore reasoned that proteins that inhibit acetylation of histones in response to TSA might also inhibit DNA demethylation. Similar proteins might also inhibit corrective demethylation of spuriously methylated genes and lead to hypermethylation of certain sequences explaining the progressive methylation of tumor suppressor genes in cancer. Recently, experiments performed by Seo et al. (2) led to the discovery of a novel human cellular complex which inhibits the histone acetyltransferase (HAT) activity of transcriptional coactivators p300/CBP and PCAF. This complex called INHAT (inhibitor of acetyltransferases) comprised of the myeloid leukemia-associated oncoprotein SET/TAF-Iβ, the template-activating factor TAF-Iα, and the nuclear phosphoprotein pp32 masks the effect of histone acetyltransferases by binding to histones, thereby inhibiting transcription and serving as a novel mechanism of transcriptional regulation (2). INHAT subunits were shown to individually inhibit histone acetylation. Since INHATs influence the state of histone acetylation (2), and since histone acetylation affects chromatin structure (11, 12), we tested the hypothesis that INHATs could directly or indirectly modulate DNA methylation patterns by inhibiting DNA methylation and thus play a role in integrating the status of histone acetylation, DNA methylation, and transcriptional silencing. Since SET/TAF-Iβ’s association with leukemia suggests a fundamental cellular function perhaps related to neoplastic progression, we focused primarily on the SET/TAF-Iβ oncoprotein in this study.

**Fig. 1.** A, Set/TAF-Iβ inhibits histone acetylation. HAT assays were performed with increasing concentrations of GST-Set/TAF-Iβ (lanes 2–4) and GST-Set/TAF-Iβ 120–225 (lanes 6–8), respectively. In lanes 1 and 5, p300 was incubated with histones only. The upper panels show Coomassie staining of both proteins used, and positions of individual histones are shown by phosphorimaging of acetylated histones (lower panels). B and C, Set/TAF-Iβ decreases acetylation-induced increase of GFP expression. B, total cell extracts from HEK293 cells transfected with either CMV-GFP plasmid alone (lanes 1–6) or CMV-GFP and Set/TAF-Iβ (lanes 7–9) in the absence (lanes 1–3) or presence of 0.3 μM TSA (lanes 4–9) were prepared using standard protocols and resolved on a 12.5% SDS-polyacrylamide gel in triplicates. C, total cell extracts from HEK cells transfected with increasing concentrations of Set/TAF-Iβ (0.1, 0.5, 1.0, and 2.0 μg) (lanes 2–5) or Set/TAF-Iβ 120–225 mutant (0.1, 0.5, 1.0, and 2.0 μg) (lanes 7–9), in the absence (lane 1) or presence of 0.3 μM TSA (lanes 2–9), were prepared using standard protocols and resolved on a 12.5% SDS-polyacrylamide gel. D, total cell extracts from HEK cells transfected with increasing concentrations of Set/TAF-Iβ (0.1, 0.5, 1.0, and 2.0 μg) (lanes 3–6) or Set/TAF-Iβ 120–225 mutant (0.1, 0.5, 1.0, and 2.0 μg) (lanes 7–10), in the absence (lane 1) or presence of 0.3 μM TSA (lanes 2–10), were prepared using standard protocols and resolved on a 12.5% SDS-polyacrylamide gel. All blots were transferred to PVDF membranes. C, GFP protein was detected using rabbit polyclonal IgG (Santa Cruz, sc-8334) at 1:5000. D, Set/TAF-Iβ protein was detected using mouse monoclonal IgG (Jackson ImmunoResearch Laboratories Inc.) at 1:20,000. Signal was detected using enhanced chemiluminescence detection kit (Amersham Biosciences). To show equal loading of the protein, membranes were stained with Amido Black (lower panels).
MATERIALS AND METHODS

Cell Culture—HEK293 cells were plated at a density of $8 \times 10^5$ cells/well in a six-well tissue culture plate and transiently transfected with 80 ng of methylated CMV-GFP plasmid DNA alone or cotransfected with up to a maximum of 2 &micro;g of INHAT plasmid DNA (2) per well, using the calcium phosphate precipitation method as described previously (13). Transfections were performed in five individual wells and were repeated three times using different cultures of HEK293 cells.

In Vitro Methylation of Substrates—CMV-GFP plasmid was methylated in vitro by incubating 10 &micro;g of plasmid DNA with 20 units of SssI CpG DNA methyltransferase (14) (New England Biolabs Inc.) in a buffer recommended by the manufacturer containing 160 &micro;M S-adenosylmethionine, at 37°C for 2 h. After repeating this procedure three times, full protection from HpaII digestion was observed.

Histone Acetylation Assays—The assay was performed essentially as described previously (2) utilizing increasing concentrations of wild type Set/TAF-I and mutant Set/TAF-I proteins. In short, ~1 pmol of baculovirus-expressed and purified p300 was incubated with (Fig. 1A, lanes 2–4 and 6–8) or without (Fig. 1, lanes 1 and 5) increasing concentrations of purified wild type or mutant GST-Set/TAF-I as indicated in the legend to Fig. 1 for 5 min at 40 °C before the addition of ~1 &micro;g of purified core histones and [14C]acetyl-CoA (1000 pmol/μl, Sigma) and incubation continued for an additional 30 min. HAT assays were performed in the presence of 10 mM sodium butyrate. Reaction products were separated by SDS-PAGE and analyzed by phosphorimager (2). GST alone had no effect in the assay system.

Bisulfite Mapping—Bisulfite mapping was performed as described previously with minor modifications (15). 5 &micro;g of sodium bisulfite-treated DNA samples were subjected to PCR amplification using the first set of primers described below. PCR products were used as templates for subsequent PCR reactions utilizing nested primers. The PCR products of the second reaction were then subcloned using the Invitrogen TA cloning kit (we followed the manufacturer’s protocol, procedure C). The primers used for the enhanced green fluorescent protein (pEGFP-1) (CLONTECH) (GenBankTM accession number U5761) were: GFP5, 5’-ttttatatgtattttggt-3’; GFP7, 5’-CCAATGATAAATGTTGAA-3’; p32, 5’-GAACTAAGTATGACAGTGA-3’; p30, 5’-CAGTATGACAGTGAGAAGA-3’. Chromatin Immunoprecipitation (CHIP) Assay—CHIP assays (16) were performed by following the Upstate Biotechnology CHIP assay kit protocol (catalog number 17-295). HEK293 cells were transfected with 80 ng of in vitro CMV-GFP plasmid, using the calcium phosphate method (see above). A final concentration of 0.3 &micro;M TSA was added or...
not added to fresh medium 24 h after transfection. Formaldehyde was added to the culture media at a final concentration of 1%, 96 h post-transfection and incubated at 37 °C for 10 min. Chromatin was immunoprecipitated using either anti-acetylated histone H3 antibody (Upstate Biotechnology) as recommended by the manufacturer or the anti-Set/TAF-I antibody (2) or rabbit preimmune serum, as a control. One-tenth of the lysate was kept to quantify the amount of DNA present in different samples before immunoprecipitation (Input). PCR reactions on DNA purified from non-immunoprecipitated samples (input) and immunoprecipitated samples (Ac H, Set/TAF-Iβ, and Pre) were repeated exhaustively using varying amounts of template to ensure that results were within the linear range of the PCR. The following primers were used to amplify the GFP gene: GFP 5′-caagggagggagttg-3′; GFP 3′, 5′-cgccatgatatagacgttg-3′.

**Western Blot Analysis**—Total cell extracts were prepared using standard protocols and resolved on SDS-polyacrylamide gel electrophoresis (12.5%). After transferring to polyvinylidene difluoride membrane (Amersham Biosciences) and blocking the non-specific binding with 5% skim milk, GFP protein was detected using rabbit polyclonal IgG (Santa Cruz, sc-8334) at 1:500 dilution, followed by peroxidase-conjugated anti-rabbit IgG (Sigma) at 1:5000, and an enhanced chemiluminescence detection kit (Amersham Biosciences). Set/TAF-Iβ protein was detected as described previously (17).

**Multiple Tumor Blot Analysis**—The matched tumor/normal expression assay membrane was hybridized using a 32P-labeled Set/TAF-Iβ cDNA, according to the CLONTECH Laboratories Inc. Matched Tumor/Normal Expression Array User Manual (catalog number 7840-1). To obtain final expression values, each hybridization signal was quantified by densitometry and normalized against signal obtained by hybridization with a cDNA probe for ubiquitin.

**RESULTS**

**INHAT Set/TAF-Iβ Inhibits Expression of a Cotransfected Methylated CMV-GFP Reporter Gene in a Dose-dependent Manner**—We utilized a previously described transient transfection-based assay system to study active demethylation of ectopically methylated DNA and the different parameters that might affect it. In prior studies we have shown that in vitro methylated CMV-GFP reporter plasmid is actively demethylated 72–96 h following transfection into human embryonic kidney HEK293 cells and that this demethylation is dramatically enhanced when histone hyperacetylation is induced pharmacologically with TSA (1). If Set/TAF-Iβ functions by inhibiting histone acetylation, and also functionally interacts with methylated CMV-GFP, then overexpression of Set/TAF-Iβ should inhibit expression of CMV-GFP. To test this, Set/TAF-Iβ plasmid was cotransfected into human embryonic kidney HEK293 cells, with in vitro methylated CMV-GFP plasmid, in the presence or absence of TSA (72 h), and harvested 96 h post-transfection. Cell extracts were prepared and subjected to Western blot analysis using antibodies directed against GFP protein (Fig. 1, B and C) or against the amino-terminal region of the Set/TAF-Iβ oncoprotein (which only recognizes the endogenous and wild type Set/TAF-Iβ construct) (Fig. 1D). GFP expression is significantly increased in the presence of TSA compared with no TSA treatment (Fig. 1B) (1); and in agreement with previous
results (2), Fig. 1A shows that while the wild type Set/TAF-Iβ inhibits p300-mediated histone acetylation in a dose-dependent manner, the mutant Set/TAF-Iβ 120–225, which lacks the previously determined HAT inhibitory domain (INHAT domain) and histone binding domain, fails to inhibit histone acetylation (Fig. 1A and Ref. 2). Cotransfection with Set/TAF-Iβ (Fig. 1, B and C), but not the mutant Set/TAF-Iβ 120–225 plasmid (Fig. 1C), attenuated GFP expression to a level that is only slightly above the basal value obtained in the absence of TSA (Fig. 1B), in a dose-dependent manner (Fig. 1, C and D), establishing a role for the INHAT activity of Set/TAF-Iβ in regulating GFP expression.

INHAT Subunits Inhibit Demethylation of Ectopically Methylated CMV-GFP Transiently Transfected into HEK293 Cells in a Dose-dependent Manner—Since different subunits of the INHAT complex inhibited expression of CMV-GFP, we determined their effect on DNA demethylation induced by TSA (1). DNA was isolated from HEK293 cells cotransfected with methylated GFP DNA and Set/TAF-Iβ, pp32, or Set/TAF-Iβ 120–225 mutant and was treated with 0.3 μM TSA for 72 h. A map of the analyzed GFP gene is presented in Fig. 2A. DNA was first linearized with the EcoRI restriction enzyme, followed by digestion with MspI (which cleaves the sequence CCGG) or HpaII (which cleaves the sequence CCGG only when it is not methylated). The results of this experiment demonstrate that histone deacetylase inhibitor (TSA) treatment alone results in nearly complete demethylation (90%) as indicated by the detection of a fully demethylated HpaII-digested fragment (529 kb) as shown previously (Fig. 2B, lane 3 and graph bar 1) (1). Remarkably, addition of individual INHAT subunits Set/TAF-Iβ and pp32, which block histone acetylation, inhibit demethylation of the reporter gene, as indicated by the 9-fold reduction in the relative abundance of the HpaII-digested fragment with Set/TAF-Iβ (Fig. 2B, compare lane 3 with lanes 6 and 9, and graph bar 2 versus bar 1). The Set/TAF-Iβ 120–225 mutant, which does not inhibit histone acetylation, had a minimal effect (2-fold) on blocking DNA demethylation (Fig. 2B, compare lane 12 with lane 6, and graph bar 3). There is a dose-response relationship between demethylation and inhibition of histone acetylation. The relative abundance of the fully demethylated 0.529-kb HpaII fragment was reduced from 95% (with TSA alone) to nearly undetectable levels (6%) with increasing doses of Set/TAF-Iβ (Fig. 2C, lanes 6, 9, 12, 15, 18, and graph open circles), but not with the Set/TAF-Iβ 120–225 mutant (Fig. 2C, lanes 21, 24, 27, 30, and graph closed squares). In summary, these experiments demonstrate that INHAT subunits inhibit demethylation of ectopically methylated DNA in a dose-dependent manner.

INHAT Subunit Set/TAF-Iβ Inhibits Demethylation by Directly Interacting with the Chromatin Associated with It—Set/TAF-Iβ might inhibit demethylation of CMV-GFP DNA indirectly by inducing other activities required for demethylation or they might act directly on CMV-GFP by binding to its chromatin and preventing its acetylation and, as a consequence, its demethylation. If Set/TAF-Iβ acts on histones associated with the target DNA, then CMV-GFP DNA associated with Set/TAF-Iβ.
Inhibitors of Histone Acetylation Inhibit DNA Demethylation

should remain hypermethylated, whereas DNAs that escaped Set/TAF-Iβ binding should be associated with acetylated histones and hypomethylated (1). To address this issue we used the CHIP assay with anti-acetyl-histone H3 and anti-Set/TAF-Iβ antibodies on cells cotransfected with methylated GFP and 1 μg of Set/TAF-Iβ (a concentration of Set/TAF-Iβ that results in partial inhibition of demethylation as shown in Fig. 2C) and treated with TSA (Fig. 3). The results presented in Fig. 3A show that the CMV-GFP gene sequence was immunoprecipitated with both the anti-acetylhistone H3 and anti-Set/TAF-Iβ antibodies but not with preimmune rabbit serum. GFP plasmid DNAs isolated from both acetylhistone H3 and Set/TAF-Iβ-immunoprecipitated samples were then subjected to bisulfite mapping to determine their respective methylation patterns (Fig. 3B). GFP DNA isolated before immunoprecipitation (Input) was partially demethylated as anticipated (Fig. 2C). All DNAs immunoprecipitated with acetylhistone H3 antibody displayed almost complete demethylation (Fig. 3, B and C). Remarkably, however, DNAs immunoprecipitated with anti-Set/TAF-Iβ antibodies appeared completely hypermethylated except for one demethylated clone. This result shows that Set/TAF-Iβ associates with methylated transfected CMV-GFP chromatin and facilitates the maintenance of the methylated status.

Set/TAF-Iβ Is Overexpressed in Multiple Tumors—To test the hypothesis that the level of expression of INHATs might vary under pathological conditions where aberrations in chromatin acetylation and DNA methylation are commonly observed, we used a cDNA expression array (Atlas59) containing mRNA from various tumors and their respective non-tumor tissues (Fig. 4). The membrane was hybridized with full-length 32P-labeled Set/TAF-Iβ cDNA and quantified by densitometry. From the multiple samples assayed for each tissue type, an increased expression of Set/TAF-Iβ in certain tumor tissues relative to normal tissues was observed (Fig. 4, A–F). The tissue averages from uterus, colon, stomach, and rectum displayed a 2-fold or greater increase in Set/TAF-Iβ expression in tumor tissues compared with normal tissues (Fig. 4G).

DISCUSSION

This paper demonstrates that a chromatin-modifying protein can determine the state of methylation of certain ectopically methylated sequences by inhibiting DNA demethylation. There are several possibilities by which INHAT subunits may regulate DNA methylation. First Set/TAF-Iβ, by virtue of its ability to inhibit histone acetylation, maintains target DNAs in hypoacetylated form. Since histone hyperacetylation is necessary for DNA demethylation of ectopically methylated DNA (1), Set/TAF-Iβ-targeted DNAs remain hypermethylated. Second, the histone binding and HAT inhibitory functions of Set/TAF-Iβ are not necessary for its role in the maintenance of DNA hypermethylation. However, the greatly reduced ability of the Set/TAF-Iβ mutant (defective in histone binding and INHAT functions) to protect methylated DNA as compared with the wild type Set/TAF-Iβ eliminates this possibility. Third, INHAT functions by directly recognizing methylated DNAs and protecting them from being targeted by DNA demethylases, which is supported by the fact that the Set/TAF-Iβ mutant still retains a minor ability to inhibit demethylation. Finally INHAT may function by both binding to methylated DNAs and preventing histone acetylation. While these remain formal possibilities and are testable, based on our results we suggest a model depicted in Fig. 5 directly linking HAT-inhibitory property, INHAT, in the establishment of an inverse relationship between histone acetylation and DNA methylation in gene silencing. Based on our previous results and the results shown here, we propose that the balance of demethylation and INHATs in cells may therefore determine the final DNA methylation pattern. Histone hypoacetylation due to an elevation in the cellular concentration of factors such as INHATs (Fig. 4G) may prevent access of demethylases to chromatin, therefore preserving the existing ectopic hypermethylation.

This paper identifies for the first time a potential mechanism of inhibition of active demethylation and further supports our previous hypothesis that cancer cells bear a level of demethylase activity that demethylates ectopically methylated sequences. Further extensive experiments are obviously required to test whether such a mechanism participates in precipitating the hypermethylated state of specific tumor suppressor genes. An obvious question that has to be addressed is how could inhibitors of demethylation cause hypermethylation of normally unmethylated genes such as tumor suppressors. We would like to speculate that spurious methylation events do occur during normal replication and that they are normally removed from transcribed genes that are associated with hyperacetylated histones by demethylase(s). Interaction of proteins such as Set/TAF-Iβ with histones associated with a gene lead to inhibition of acetylation, and as a consequence corrective demethylation is inhibited. This can lead to progressive hypermethylation of a gene. In summary, this paper demonstrates that a protein that inhibits histone acetylation also blocks demethylation as well as expression of ectopically methylated DNA. This is to our knowledge the first example of a class of proteins shown to affect a methylation pattern by inhibiting demethylation. These data redirect our understanding of how DNA methylation patterns are generated, maintained, and pathologically altered in cancer and provide novel potential targets for regulation of aberrant methylation patterns, such as those found in tumors or transformed cells.

While our experiments suggest that Set/TAF-Iβ could potentially affect DNA methylation states by inhibiting demethylation, further experiments will be necessary to demonstrate that hypermethylation of specific tumor suppressor genes involves interaction with proteins like Set/TAF-Iβ. We are currently searching for endogenous genes targeted by INHATs, to test our model and confirm the results of our transient system. Other important questions that have to be resolved are what are the mechanisms responsible for up-regulation of Set/TAF-Iβ during tumorigenesis and what may target Set/TAF-Iβ to certain genes and not others? Nevertheless, our data illustrates some of the first principles integrating the process of demethylation, histone hypoacetylation, and DNA hypermethylation in the establishment of silent chromatin loci.

REFERENCES

1. Cervoni, N., and Szyf, M. (2001) J. Biol. Chem. 276, 40778–40787
2. Sco, S. B., McNamara, P., Heo, S., Turner, A., Lane, W. S., and Chakravarti, D. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 119–139
3. Razin, A., and Cedar, H. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 2725–2728
4. Razin, A. (1998) EMBO J. 17, 4965–4968
5. Szyf, M., Kaplan, F., Mansuy, I., Glob, H., Kedar, E., and Razin, A. (1985) J. Biol. Chem. 260, 8653–8656
6. Selker, E. U. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 9430–9435
7. Tamarsu, H., and Selker, E. U. (2001) Nature 414, 377–283
8. Di Croce, L., Raker, V. A., Corsaro, M., Fazzi, F., Fanelli, M., Faretta, M., Fukuoka, T., Lu Calvo, F., Kourzides, T., Nervi, C., Minucci, S., and Pelicci, P. G. (2002) Science 295, 1079–1082
9. Ramechandani, S., Bhattacharyya, S. K., Cervoni, N., and Szyf, M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 6107–6112
10. Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G., and Baylin, S. B. (1999) Nat. Genet. 21, 103–107
11. Chen, H., Tini, M., and Evans, R. M. (2001)Curr. Opin. Cell Biol. 13, 218–224
12. Jenuwein, T., and Allis, C. D. (2001) Science 293, 1074–1080
13. Rouleau, J., Tanigawa, G., and Szyf, M. (1992) J. Biol. Chem. 267, 7366–7377
14. Nar, I., Szyf, M., Razin, A., Glaser, G., Rettem, S., and Razin, S. (1985) J. Bacteriol. 164, 19–24
15. Clark, S. J., Harrison, J., Paul, C. L., and Froomer, M. (1994) Nucleic Acids Res. 22, 2990–2997
16. Crane-Robinson, C., Myers, F. A., Hebbes, T. R., Clayton, A. L., and Thorne, A. W. (1999) Methods Enzymol. 304, 533–547
17. Nagata, K., Saito, S., Okuwa, M., Kawase, H., Furuya, A., Kusano, A., Hanai, N., Okuda, A., and Kikuchi, A. (1998) Exp. Cell Res. 240, 274–281
The Oncoprotein Set/TAF-1β, an Inhibitor of Histone Acetyltransferase, Inhibits Active Demethylation of DNA, Integrating DNA Methylation and Transcriptional Silencing
Nadia Cervoni, Nancy Detich, Sang-beom Seo, Deabrat Chakravarti and Moshe Szyf

J. Biol. Chem. 2002, 277:25026-25031.
doi: 10.1074/jbc.M202256200 originally published online April 26, 2002

Access the most updated version of this article at doi: 10.1074/jbc.M202256200

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 17 references, 10 of which can be accessed free at http://www.jbc.org/content/277/28/25026.full.html#ref-list-1